• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

REPLACE DARE Score Provides Novel Tool for Risk Stratifying Patients Requiring Pacemaker or ICD Replacement

, Medizintechnik, BIOTRONIK

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today the publication of new findings from the REPLACE Registry...

Einführung der elektronischen Abrechnung (DTA) in den Bereichen Rehabilitationssport, Herzsport und Funktionstraining beim vdek

, Medizintechnik, Deutsches Medizinrechenzentrum GmbH

Sportvereine, Fitnessstudios, private Sportgruppen und Physiotherapie-Praxen, die Rehabilitationssport­, Herzsport oder Funktionstraining anbieten,...

W&H Synea Vision Short Edition: The perfect balance between contra-angle handpiece and powerful electric motor

, Medizintechnik, W&H Dentalwerk Bürmoos GmbH

The new W&H Synea Vision Short Edition showcases a high-quality range of contra-angle handpieces that are significantly lighter and shorter and...

Disclaimer